NPM1 and acute myeloid leukemia: We therefore considered a large independent cohort of AML patients34 and found a significant enrichment of DNMT3A-R882 and NPM1 co-mutations and a significant enrichment of concurrent DNMT3A-R882, NPM1, FLT3 mutations compared to the corresponding groups of patients with other DNMT3A mutations (Supplementary Fig. 4, Fisher’s exact test: P < 0.01), whereas no significant difference in the proportion of FLT3 mutations was found.